Research partners will target neurodegenerative disease

Neurons in Parkinson's disease

X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.  

Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease. 

“We appreciate being a preferred partner to support drug discovery projects across the Sironax portfolio,” said X-Chem CEO Matt Clark. “The combination of Sironax’s deep scientific knowledge and our leading DEL platform will help drive the discovery of new therapeutics that will help patients.” 

 X-Chem provides services to pharmaceutical and biotech companies for screening, hit validation and lead optimisation. Its DEL platform is designed to discover novel small molecule leads against challenging, high-value therapeutic targets. 

Sironax is a clinical-stage biotechnology company focused on age-related degenerative diseases. The company’s pipeline targets key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free